| Literature DB >> 35547743 |
Beiming Yu1, Feng Wang1, Yanfeng Wang1.
Abstract
SHARPIN was initially found as a SHANK-associated protein. SHARPIN can be used as an important component to form the linear ubiquitin chain assembly complex (LUBAC) with HOIL-1L, HOIP to produce a linear ubiquitin chain connected N-terminal Met1, playing a critical role in various cellular processes including NF-κB signaling, inflammation, embryogenesis and apoptosis. SHARPIN alone can also participate in many critical physiological activities and cause various disorders such as chronic dermatitis, tumor, and Alzheimer's disease. Mice with spontaneous autosomal recessive mutations in the SHARPIN protein mainly exhibit chronic dermatitis and immunodeficiency with elevated IgM. Additionally, SHARPIN alone also plays a key role in various cellular events, such as B cells activation and platelet aggregation. Structural studies of the SHARPIN or LUBAC have been reported continuously, advancing our understanding of it at the molecular level. However, the full-length structure of the SHARPIN or LUBAC was lagging, and the molecular mechanism underlying these physiological processes is also unclear. Herein, we summarized the currently resolved structure of SHARPIN as well as the emerging physiological role of SHARPIN alone or in LUBAC. Further structural and functional study of SHARPIN will provide insight into the role and underlying mechanism of SHARPIN in disease, as well as its potential application in therapeutic.Entities:
Keywords: SHARPIN alone; SHARPIN in LUBAC; cellular role; physiological function; structure
Mesh:
Substances:
Year: 2022 PMID: 35547743 PMCID: PMC9084887 DOI: 10.3389/fimmu.2022.858505
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 8.786
Figure 1A schematic diagram showing the domain architectures of SHARPIN, HOIP, and HOIL-1L proteins. Structures are shown where available and include the PH domain of SHARPIN (4EMO); HOIP PUB (4OYK), HOIP ZF/NEMO UBAN (4OWF), HOIL-1L UBL/HOIP UBA/SHARPIN UBL complex(5Y3T), HOIP RBR/UBE2D2-ubiquitin (5EDV) and the HOIL-1L NZF/linear diUb complex (3B08).The phosphorylation of Ser165 of SHARPIN can be involved in the activation of NF-κB. The phosphorylation of Ser146 of SHARPIN promotes the metastatic spread of cancer cells through an interaction with ARP2/3.
SHARPIN connected with pathophysiological processes via different signaling pathway.
| Targeted Process | Diseases | Cellular effects | Targeted signaling pathway | SHARPIN Overexpression/Knockdown |
|---|---|---|---|---|
| Immune response | Chronic proliferative dermatitis mutation (cpdm) mice | Cpdm mice are deficient in SHARPIN and develop dermatitis, multi-organ pathology and an immunological phenotype | SHARPIN deficiency blunts the TNFR1 pro-survival transcriptional signal and sensitizes cells to TNF-induced cell death | SHARPIN deficiency can sensitize TNF/TNFR1-induced caspase-8-mediated apoptosis and thus hyperapoptosis induces an inflammatory response |
| Branchio-oto-renal (BOR) | Characterized by kidney defects, hearing loss, and branchial arch abnormalities | SHARPIN can enhance the function of the Eya protein | The BOR syndrome was demonstrated in zebrafish after knockdown of SHARPIN | |
| Inflammatory NF-κB signaling pathway | SHARPIN-mediated linear ubiquitination regulates the NF-kB signaling activation | Promote IkBα deubiquitinatin | P50 and p65 levels were elevated in activated NF-κB complexes after LUBAC overexpression | |
| Platelet aggregation | SHARPIN inhibits integrin activation and platelet aggregation | SHARPIN is found to be expression in platelets, can respond associated with aIIbβ3, inhibit aIIbβ3 activation with aIIb | Loss of SHARPIN correlates with increased β3-intergin activity | |
| Cancer | Tumorigenesis | SHARPIN expressing CHO-K7 cells produced 1.6 times more colonies than the vector-transfected cells | SHARPIN suppresses the PIP3 (phosphorylation of 3 phosphate, PIP3) phosphorylation through its ubiquitin-like domain and PTEN interaction | The tumorigenic properties of CHO-K7 cells are significantly promoted upon SHARPIN overexpression, suggesting that SHARPIN has proto-oncogenic effects |
| SHARPIN promotes the formation of lamellipodium through the ARP2/3 complex | SHARPIN serine 146 phosphorylation promotes the metastatic spread of cancer cells through an interaction with ARP2/3 | Overexpressed SHARPIN promotes cancer cell proliferation, | ||
| Breast cancer | Regulates the ERαprotein ubiquitination and promote breast cancer growth | Overexpression of SHARPIN significantly increased ERα protein levels | Overexpression of SHARPIN in breast cancer is correlated with ERα protein levels, and that SHARPIN can promote breast cancer development by regulating the ubiquitination of ERα proteins, during which SHARPIN is not involved in regulating gene expression | |
| Depleted SHARPIN resulted in decreased cell proliferation and enhanced expression of p53 | SHARPIN modulates the p53 protein levels through poly-ubiquitination and degradation in a MDM2-dependent manner | Knock down SHARPIN enhanced expression of p53 | ||
| Colon carcinoma cell | SHARPIN with PRMT5 contributes to regulating the transcription of cancer-associated genes | SHARPIN regulates p53 through PRMT5-dependent signaling with PAX3 and MITF | Unknown | |
| Esophageal cancer | SHARPIN inhibits Esophageal cancer cell progression by promoting YAP degradation | SHARPIN can promote YAP K48-linked ubiquitination and degradation | Modulation SHARPIN expression level could inhibit cancer cell progression in Esophageal cancer | |
| Renal cell carcinoma | SHARPIN promotes the development of renal cell carcinoma | Enhance pVHL protein ubiquitination and degradation | Overexpression of SHARPIN leads to elevated intracellular HIF2α in patients with Renal cell carcinoma. SHARPIN can promote polyubiquitination of pVHL and thus degradation by the proteasome, which causes HIF-2α to escape the fate of ubiquitination and successfully into the nucleus to function | |
| Melanoma | SHARPIN promotes Melanoma Progression | SHARPIN upregulates Rap activation which can promote the invasion and metastasis of human melanoma cells | Unknown | |
| Neurodegenerative diseases | Alzheimer’s disease (AD) | SHARPIN-mediated inflammation in macrophages exposed to Aββ promoted the neuronal cell death | SHARPIN is required for NLRP3 activation | SHARPIN knockdown attenuated Aβ-induced NLRP3 expression in macrophages |
Figure 2Difference between SHARPIN presence and absence in regulating the NF-κB signaling pathway and integrin activation. (A) Normal SHARPIN expression. SHARPIN is found to be expression in platelets, can respond associated with aIIbβ3, inhibit aIIbβ3 activation with aIIb, and can also participate in the formation of LUBAC, thereby promoting Met1 ubiquitination. Stimulation of platelets through receptors for TNFα, LPS, 1l-1β or CD40 activates LUBAC to add Met1 linear ubiquitin chains (yellow circles) to NEMO, provoking transautophosphorylation of IKKβ and phosphorylation of IκBα. In nucleated cells, Lys-48-ubiquitination (yellow circles) results in degradation of IκBα, which frees NF-κB for nuclear translocation. (B) Effects of SHARPIN knockdown. Reduction of SHARPIN levels associated with αIIb prime αIIbβ3 activation and fibrinogen binding. Reduction in SHARPIN levels also destabilize LUBAC. Only a selected number of factors of the TNFR1-associated signaling complex are depicted.
Figure 3SHARPIN regulates multiple signaling pathways during tumorigenesis. SHARPIN suppresses the PIP3 phosphorylation through its ubiquitin-like domain and PTEN interaction which mediates tumorigenesis; SHARPIN upregulates Rap activation which can promote the invasion and metastasis of human melanoma cells; SHARPIN can promote breast cancer development by regulating the ubiquitination of ERα proteins; SHARPIN regulates p53 through PRMT5-dependent signaling with PAX3 and MITF, which promotes tumorigenesis; SHARPIN also functions to inhibit P53 protein stability via MDM2; SHARPIN inhibits Esophageal cancer cell progression by promoting YAP K48-linked ubiquitination and degradation; SHARPIN can promote polyubiquitination of pVHL and thus degradation by the proteasome, which causes HIF-2α to escape the fate of ubiquitination and successfully into the nucleus to function which promotes the development of renal cell carcinoma.
| Ub | Ubiquitin |
| E1 | Ub-activating enzyme |
| E2 | Ub-conjugating enzyme |
| E3 | Ub ligase |
| LUBAC | The linear ubiquitin chain assembly complex |
| SHARPIN | SHANK-associated RH domain-interacting protein |
| HOIP | Ring finger protein 31 |
| HOIL-1L | RanBP-type and C3HC4-type zinc finger containing 1 |
| cpdm | chronic proliferative dermatitis mice |
| UBL | ubiquitin-like domain |
| NZF | Npl4-zinc finger domain |
| UBA | ubiquitin-associated domain |
| RBR | RING-between RING |
| PUB | UBX-containing protein |
| ZF | zinc finger |
| NZF | Nlp4-like ZF domains |
| LDD | linear Ub chain determining domain |
| NEMO | Inhibitor of kappaB kinase gamma |
| NF-κB | Nuclear factor kappa B |
| LTM | LUBAC-tethering motif |
| TD | Tethering domain |
| ATM | ataxia telangiectasia mutated |
| IKKα | Nuclear factor of kappa light polypeptide gene enhancer, alpha |
| IKKβ | Nuclear factor of kappa light polypeptide gene enhancer,beta |
| Eya1 | Eyes absent 1 protein |
| BOR | Branchio-oto-renal |
| TNF | tumor necrosis factor |
| TRADD | TNFR1-associated death domain protein |
| TRAF2 | TNF receptor-associated factor 2 |
| cIAPs | cellular inhibitor of apoptosis |
| RIPK1 | receptor interacting protein kinase 1 |
| PTEN | phosphatase and tensin homolog |
| PTEN-NRs | negative regulatory protein of PTEN |
| SIPL1 | class SHANK interacting protein 1 |
| PIP3 | phosphorylation of 3 phosphate |
| ERα | estrogen receptor alpha |
| MDM2 | (mouse double minute 2 homolog |
| Rap1 | Ras-associated protein-1 |
| Pvhl | Von Hippel-Lindau protein |
| HIF | hypoxia-induced factor |
| PHD | prolyl hydroxylase domain-containing protein |
| AD | Alzheimer’s disease |
| Aβ | amyloid-beta |
| LOAD | late-onset Alzheimer’s disease |